Replies to post #2665 on Synaptogenix Inc (SNPX)

[donsker]

Blu 1, I think I heard from Sylvania Radio that they're behind NTRP. I mean, what does that mean that Bloomberg says its' one year -- BIIB in 2019 on plaque, so what? Investors are fleeing because plaque and tau is a fool's pursuit, but BIIB won't report until 2019. Wow. And a FDA approved 2b against moderate to severe AZ is new, the science is new, and the placebo effect is minimized. What's not to like where its double blind, placebo controlled. Yes or no in 30 days. For an investor and a speculator it means: Man up or short elsewhere.

[Whatsupp]

The difference with NTRP and those others is that their 2b and 3 trials are addressing moderate to severe patients, no one has ever attempted that. Most small bio's only handle mild and run small long trials to milk the investors. If they cannot data mine enough FUD, they start pushing other drugs as their savior.

[runncoach]

Why do the patients want to continue on the drug is the better question. Why drag 2b out if you know enough about the MOA in 12 weeks to be able to move forward?